Corrigendum to Active Extramedullary Disease Predicts ICANS and Early ICAHT after CAR-T Therapy in Multiple Myeloma Transplantation and Cellular Therapy 31/2S (2025) S409 (Transplantation and Cellular Therapy (2025) 31(2S), (S2666636725006487), (10.1016/j.jtct.2025.01.628))

Andrew J. Portuguese*, Emily C. Liang, Jennifer J. Huang, Lorenzo Iovino, Natalie Wuliji, Danai Dima, Rahul Banerjee, Mary L. Kwok, Kara I. Cicero, Mazyar Shadman, Andrew J. Cowan, Jordan Gauthier

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

The authors regret that the acronym ICAHT was incorrectly expanded in the original article. The correct expansion of ICAHT is “immune effector cell-associated hematotoxicity,” not “immune effector cell-associated hemophagocytic syndrome.” The authors would like to apologize for any inconvenience caused.

Original languageEnglish
JournalTransplantation and Cellular Therapy
DOIs
StateAccepted/In press - 2025
Externally publishedYes

Cite this